| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 1999;100:1847-1850.)
© 1999 American Heart Association, Inc.
Brief Rapid Communications |
From the Medizinische Universitätsklinik Würzburg (S.N., H.R., M.S., M.H., F.W., G.E.) and the Abteilung für Molekulare Kardiologie, Göttingen University (J.P., G.H.), Germany, and the Institute for Cell Biology, ETH-Hönggerberg, Zürich, Switzerland (B.W., T.W.).
Correspondence to Stefan Neubauer, MD, Medizinische Universitätsklinik, Josef-Schneider-Straße 2, 97080 Würzburg, FRG. E-mail s.neubauer{at}mail.uni-wuerzburg.de
| Abstract |
|---|
|
|
|---|
Methods and ResultsCreatine transporter protein was quantified in nonfailing and failing human myocardium (explanted hearts with dilated cardiomyopathy [DCM; n=8] and healthy donor hearts [n=8]) as well as in experimental heart failure (residual intact left ventricular tissue, rats 2 months after left anterior descending coronary artery ligation [MI; n=8] or sham operation [sham; n=6]) by Western blotting. Total creatine content was determined by high-performance liquid chromatography. Donor and DCM hearts had total creatine contents of 136.4±6.1 and 68.7±4.6 nmol/mg protein, respectively (*P<0.05); creatine transporter protein was 25.4±2.2 optical density units in donor and 17.7±2.5 in DCM (*P<0.05). Total creatine was 87.5±4.2 nmol/mg protein in sham and 65.7±4.2 in MI rats (*P<0.05); creatine transporter protein was 139.0±8.7 optical density units in sham and 82.1±4.0 in MI (*P<0.05).
ConclusionsBoth in human and in experimental heart failure, creatine transporter protein content is reduced. This mechanism may contribute to the depletion of creatine compounds and thus to the reduced energy reserve in failing myocardium. This finding may have therapeutic implications, suggesting a search for treatment strategies targeted toward creatine transport.
Key Words: sodium creatine myocardium heart failure
| Introduction |
|---|
|
|
|---|
| Methods |
|---|
|
|
|---|
50 mg were homogenized as
described below.
Rat Model of Chronic Myocardial Infarction
Infarcts (left anterior descending coronary artery
ligation: n=8 surviving animals) or sham operations (n=6) were carried
out in 12-week-old Wistar rats as described.3 Two months
later, rats were reanesthetized, and pressure was measured in
the right carotid artery and in the left ventricle under spontaneous
respiration as described.10 Thereafter, hearts were
isolated and buffer-perfused for 2 minutes to rinse off blood. Finally,
an
100-mg biopsy of noninfarcted left ventricular tissue
was rapidly frozen. Investigations were approved by local
authorities.
Western Blotting
A Western blot for quantification of creatine transporter
was established by our group using antibodies raised against a COOH
terminal 15-mer synthetic peptide that specifically recognizes two
55-kDa and 70-kDa polypeptides.5 These 2 protein bands
were downregulated and upregulated in skeletal muscles after long-term
feeding with creatine and guanidinopropionate (a competitive blocker of
creatine entry into muscle cells), respectively, demonstrating that
both polypeptides are indeed related to creatine
transport.5
Preparation of Rat Tissue Extracts
Heart tissue from sham-operated and infarcted rats was removed
and placed in cold (4°C) MSH buffer (220 mmol/L
D-mannitol, 70 mmol/L sucrose, 10 mmol/L HEPES,
pH 7.4). The tissue was homogenized in 2 to 3 vol MSH at
4°C. The pellet of a first centrifugation at
20 000g for 20 minutes was resuspended in MSH buffer. The
creatine transporter protein from this pellet was extracted for 30
minutes on ice in the presence of 1% Triton X-100. Extracted proteins
were then centrifuged at 10 000g for 10 minutes.
Supernatants served as tissue extracts and were kept at -80°C.
Noncollagen protein concentration was determined as
described.3
Electrophoretic Techniques and Immunoblotting
SDS-PAGE was performed according to Laemmli11
on a 12% polyacrylamide gel, with 10 µg of tissue extract
protein loaded per lane. After electrophoresis, separated proteins were
blotted semidry onto nitrocellulose paper. Unspecific sites were
blocked by a solution containing 3% fat-free milk powder in PBS.
Papers were labeled with polyclonal antiCOOH-terminal
anticreatine transporter protein antibodies characterized
previously5 (at 1:2500 dilution in blocking solution) for
2 to 3 hours at 22°C. After 3 washes with blocking buffer, membranes
were incubated with the secondary antibody (goat anti-rabbit IgG
conjugated with horseradish peroxidase and diluted 1:5000 in blocking
buffer). For detection, peroxidase reaction was carried out by
enzyme-linked chemiluminescence (Amersham RPN 2106) and exposure to
x-ray film for 5 to 20 seconds. The sum of both 55-kDa and 70-kDa
polypeptide bands was quantified by computerized blot scanning and
measurement of optical density. To improve accuracy, each sample was
analyzed 4 times, and average values were calculated.
Measurement of Total Creatine Content
Human and rat left ventricular tissue was
analyzed for total creatine content by high-performance
liquid chromatography and for noncollagen protein as
previously described.12
Statistical Analysis
Failing and nonfailing groups were compared by an unpaired
t test (significance level, P<0.05).
Correlations were tested with linear regression.
| Results |
|---|
|
|
|---|
|
|
Rat Myocardium
Left ventricular end-diastolic pressure
was 5±1 mm Hg in sham and 23±1 mm Hg (range 21 to 29
mm Hg) in failing rats (*P<0.05). Left
ventricular systolic pressures were 118±3 and
123±2 mm Hg, respectively (P=NS).
Left ventricular total creatine content was significantly
decreased, by 25%, in failing rats (Figure 1
). Figure 2
also demonstrates typical Western blots, indicating a substantial
reduction of creatine transporter protein content in failing rat
myocardium. On average, creatine transporter was decreased
by 41%. Linear correlations were found both between total creatine
content and creatine transporter (r=0.62) and between left
ventricular end-diastolic pressure and creatine
transporter (r=0.86).
| Discussion |
|---|
|
|
|---|
50 µmol/L,5 whereas fasting and
postprandial creatine serum levels are 0.2 to 0.5 and up to 3
mmol/L,13 respectively. Thus, the creatine transporter
normally operates at or close to saturating levels of extracellular
creatine. Because, in addition, degradation of creatine is nonenzymatic
and most likely not regulated, these findings strongly suggest that one
cause of creatine depletion in failing myocardium is a
reduction of the expression and accumulation of creatine transporter.
The fact that correlation coefficients for creatine and creatine
transporter were 0.51 and 0.62, however, only suggests that other
additional mechanisms regulating creatine content exist. Although creatine transporter downregulation most likely contributes to creatine depletion in heart failure, the reasons for the loss of creatine transporter are currently unknown. At present, few data exist on the mechanisms regulating this transporter. Because the creatine transporter is a Na+-cotransporter,7 in cell culture, creatine transporter kinetics were acutely dependent on Na+/K+-ATPase activity. Also, ß2-receptor stimulation and thyroid hormone14 stimulate creatine uptake. Both in human muscle cells and in G8 myoblasts, creatine transporter activity was downregulated by high and upregulated by low extracellular creatine concentrations.15 However, in heart failure, serum creatine levels remain unchanged,16 and none of these findings can explain the decrease of creatine transporter observed in failing myocardium. Thus, the mechanisms responsible for creatine transporter downregulation in heart failure remain to be determined.
Does the reduction of the creatine transporter constitute a pathophysiological or an adaptive mechanism in heart failure? The former would have to be mediated by the reduction of total creatine content. Although parallel reductions of both phosphorylated and nonphosphorylated creatine would not affect free ADP or the free energy change of ATP hydrolysis, they substantially reduce the rate and extent of intracellular ATP transfer via the creatine kinase reaction.3 Furthermore, a reduction of cellular creatine levels would reduce creatine-stimulated respiration17 and thus compromise the rate of mitochondrial energy production. In line with this observation, contractile reserve is limited when creatine levels are substantially depleted.18 Whether the depletion of total and phosphorylated creatine is a mechanism that directly contributes to heart failure has been a matter of intense debate (see Reference 4 for review), but this question is still not answered unequivocally. At the same time, it is also conceivable that reduction of total creatine in heart failure is an adaptive response slowing ATP delivery for contraction, thereby preserving energy to maintain cell viability.
If reductions of creatine content do in fact play a causal role in heart failure, then strategies to maintain the creatine transporter at normal or even supernormal levels might be a promising new treatment strategy for heart failure. At present, this remains speculative, but it may be achievable either via gene transfer or transgenic overexpression. Such studies will reveal whether providing additional creatine transporter molecules to the failing cardiomyocyte has protective effects.
| Acknowledgments |
|---|
Received August 5, 1999; revision received August 25, 1999; accepted September 7, 1999.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
H. J. Eisen Exercise Training and Myocardial Energetics in Patients With Heart Failure: When More Is Less J. Am. Coll. Cardiol., May 13, 2008; 51(19): 1892 - 1895. [Full Text] [PDF] |
||||
![]() |
J. Feygin, A. Mansoor, P. Eckman, C. Swingen, and J. Zhang Functional and bioenergetic modulations in the infarct border zone following autologous mesenchymal stem cell transplantation Am J Physiol Heart Circ Physiol, September 1, 2007; 293(3): H1772 - H1780. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. R. Lamberts, E. Caldenhoven, M. Lansink, G. Witte, R. J. Vaessen, J. A. St Cyr, and G. J. M. Stienen Preservation of diastolic function in monocrotaline-induced right ventricular hypertrophy in rats Am J Physiol Heart Circ Physiol, September 1, 2007; 293(3): H1869 - H1876. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Peluffo and R. Radi Biochemistry of protein tyrosine nitration in cardiovascular pathology Cardiovasc Res, July 15, 2007; 75(2): 291 - 302. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Neubauer The Failing Heart -- An Engine Out of Fuel N. Engl. J. Med., March 15, 2007; 356(11): 1140 - 1151. [Full Text] [PDF] |
||||
![]() |
A. V. Naumova, V. P. Chacko, R. Ouwerkerk, L. Stull, E. Marban, and R. G. Weiss Xanthine oxidase inhibitors improve energetics and function after infarction in failing mouse hearts Am J Physiol Heart Circ Physiol, February 1, 2006; 290(2): H837 - H843. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Fan, D. A. Iacobas, D. Zhou, Q. Chen, J. K. Lai, O. Gavrialov, and G. G. Haddad Gene expression and phenotypic characterization of mouse heart after chronic constant or intermittent hypoxia Physiol Genomics, August 11, 2005; 22(3): 292 - 307. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. G. Weiss, G. Gerstenblith, and P. A. Bottomley ATP flux through creatine kinase in the normal, stressed, and failing human heart PNAS, January 18, 2005; 102(3): 808 - 813. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Ingwall and R. G. Weiss Is the Failing Heart Energy Starved?: On Using Chemical Energy to Support Cardiac Function Circ. Res., July 23, 2004; 95(2): 135 - 145. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Ventura-Clapier, A. Garnier, and V. Veksler Energy metabolism in heart failure J. Physiol., February 15, 2004; 555(1): 1 - 13. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Nakae, K. Mitsunami, T. Omura, T. Yabe, T. Tsutamoto, S. Matsuo, M. Takahashi, S. Morikawa, T. Inubushi, Y. Nakamura, et al. Proton magnetic resonance spectroscopy can detect creatine depletion associated with the progression of heart failure in cardiomyopathy J. Am. Coll. Cardiol., November 5, 2003; 42(9): 1587 - 1593. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J. Brault, K. A. Abraham, and R. L. Terjung Muscle creatine uptake and creatine transporter expression in response to creatine supplementation and depletion J Appl Physiol, June 1, 2003; 94(6): 2173 - 2180. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Boehm, S. Chan, M. Monfared, T. Wallimann, K. Clarke, and S. Neubauer Creatine transporter activity and content in the rat heart supplemented by and depleted of creatine Am J Physiol Endocrinol Metab, February 1, 2003; 284(2): E399 - E406. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Scheubel, M. Tostlebe, A. Simm, S. Rohrbach, R. Prondzinsky, F. N. Gellerich, R.-E. Silber, and J. Holtz Dysfunction of mitochondrial respiratory chain complex I in human failing myocardium is not due to disturbed mitochondrial gene expression J. Am. Coll. Cardiol., December 18, 2002; 40(12): 2174 - 2181. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. S. Queiroz, Y. Shao, D. A. Berkich, K. F. Lanoue, and F. Ismail-Beigi Thyroid hormone regulation of cardiac bioenergetics: role of intracellular creatine Am J Physiol Heart Circ Physiol, December 1, 2002; 283(6): H2527 - H2533. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Beer, T. Seyfarth, J.o. Sandstede, W. Landschutz, C. Lipke, H. Kostler, M. von Kienlin, K. Harre, D. Hahn, and S. Neubauer Absolute concentrations of high-energy phosphate metabolites in normal, hypertrophied, and failing human myocardium measured noninvasively with 31P-SLOOP magnetic resonance spectroscopy J. Am. Coll. Cardiol., October 2, 2002; 40(7): 1267 - 1274. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Walzel, O. Speer, E. Zanolla, O. Eriksson, P. Bernardi, and T. Wallimann Novel Mitochondrial Creatine Transport Activity. IMPLICATIONS FOR INTRACELLULAR CREATINE COMPARTMENTS AND BIOENERGETICS J. Biol. Chem., September 27, 2002; 277(40): 37503 - 37511. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Walzel, O. Speer, E. Boehm, S. Kristiansen, S. Chan, K. Clarke, J. P. Magyar, E. A. Richter, and T. Wallimann New creatine transporter assay and identification of distinct creatine transporter isoforms in muscle Am J Physiol Endocrinol Metab, August 1, 2002; 283(2): E390 - E401. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Spindler, R. Niebler, H. Remkes, M. Horn, T. Lanz, and S. Neubauer Mitochondrial creatine kinase is critically necessary for normal myocardial high-energy phosphate metabolism Am J Physiol Heart Circ Physiol, August 1, 2002; 283(2): H680 - H687. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Horn, H. Remkes, H. Stromer, C. Dienesch, and S. Neubauer Chronic Phosphocreatine Depletion by the Creatine Analogue {beta}-Guanidinopropionate Is Associated With Increased Mortality and Loss of ATP in Rats After Myocardial Infarction Circulation, October 9, 2001; 104(15): 1844 - 1849. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Persky and G. A. Brazeau Clinical Pharmacology of the Dietary Supplement Creatine Monohydrate Pharmacol. Rev., May 11, 2001; (2001) 1. [Abstract] [Full Text] |
||||
![]() |
Y. Ye, G. Gong, K. Ochiai, J. Liu, and J. Zhang High-Energy Phosphate Metabolism and Creatine Kinase in Failing Hearts : A New Porcine Model Circulation, March 20, 2001; 103(11): 1570 - 1576. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Murphy, G. McConell, D. Cameron-Smith, K. Watt, L. Ackland, B. Walzel, T. Wallimann, and R. Snow Creatine transporter protein content, localization, and gene expression in rat skeletal muscle Am J Physiol Cell Physiol, March 1, 2001; 280(3): C415 - C422. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. O.'t Eijnde, B. Ursø, E.A. Richter, P.L. Greenhaff, and P. Hespel Effect of Oral Creatine Supplementation on Human Muscle GLUT4 Protein Content After Immobilization Diabetes, January 1, 2001; 50(1): 18 - 23. [Abstract] [Full Text] |
||||
![]() |
Creatine Cotransporter Deficient in Heart Failure Journal Watch Cardiology, December 10, 1999; 1999(1210): 3 - 3. [Full Text] |
||||
![]() |
A. M. Persky and G. A. Brazeau Clinical Pharmacology of the Dietary Supplement Creatine Monohydrate Pharmacol. Rev., June 1, 2001; 53(2): 161 - 176. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. T. Tran, W. Dai, and H. K. Sarkar Cyclosporin A Inhibits Creatine Uptake by Altering Surface Expression of the Creatine Transporter J. Biol. Chem., November 10, 2000; 275(46): 35708 - 35714. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1999 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |